DrugPatentWatch Database Preview
Drugs in Development Information for Talinolol
What is the drug development status for Talinolol?
Talinolol is an investigational drug.
There have been 4 clinical trials for Talinolol.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2011.
The most common disease conditions in clinical trials are Obesity, Morbid and [disabled in preview]. The leading clinical trial sponsors are University Medicine Greifswald, Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH, and Matthias Schwab.
There are three hundred and eighty-one US patents protecting this investigational drug and three international patents.
Summary for Talinolol
| US Patents | 381 |
| International Patents | 3,195 |
| US Patent Applications | 708 |
| WIPO Patent Applications | 462 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2011-04-01) |
| Vendors | 32 |
Recent Clinical Trials for Talinolol
| Title | Sponsor | Phase |
|---|---|---|
| Open Label Study for the Functional Characterization of Drug Metabolism and Transport | Matthias Schwab | Phase 1 |
| Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water | University Medicine Greifswald | Phase 1 |
| Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | Phase 1 |
Clinical Trial Summary for Talinolol
Top disease conditions for Talinolol
Top clinical trial sponsors for Talinolol
US Patents for Talinolol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Talinolol | Start Trial | Drug device configured for wireless communication | Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ) | Start Trial |
| Talinolol | Start Trial | Inhalable pharmaceutical compositions | iCeutica Pty Ltd. (Iluka, WA, AU) | Start Trial |
| Talinolol | Start Trial | Pyrimidines as sodium channel blockers | Purdue Pharma L.P. (Stamford, CT) | Start Trial |
| Talinolol | Start Trial | Compounds that are ERK inhibitors | Merck, Sharp & Dohme Corp. (Rahway, NJ) | Start Trial |
| Talinolol | Start Trial | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATONAL GMBH (DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Talinolol
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Talinolol | European Patent Office | 3151906 | 2034-06-03 | Start Trial |
| Talinolol | World Intellectual Property Organization (WIPO) | 2015187289 | 2034-06-03 | Start Trial |
| Talinolol | Australia | 2013227351 | 2032-02-28 | Start Trial |
| Talinolol | Australia | 2016202881 | 2032-02-28 | Start Trial |
| Talinolol | Australia | 2017213466 | 2032-02-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
